ReviewPharmaceuticals (Basel, Switzerland)2024
A Comprehensive Review and Update on Cannabis Hyperemesis Syndrome.
Review in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Patient-reported outcomes in cannabinoid hyperemesis syndrome patients treated in the emergency department: a pilot study.Clinical and experimental emergency medicine · 2026Article
- [The cannabinoid hyperemesis syndrome-A narrative review].Der Nervenarzt · 2026Review
- Links between Cannabinoid Hyperemesis Syndrome symptoms and drug use, mental health problems, antisocial behavior, and personality in a national survey of adults in the United States.medRxiv : the preprint server for health sciences · 2026Article
- Elevated suicidal thoughts and behaviors, proximal suicide risk factors, and non-suicidal self-injury among adults reporting symptoms of Cannabinoid Hyperemesis Syndrome: Results from a national survey of US adults.medRxiv : the preprint server for health sciences · 2026Article
- Antiemetic Efficacy of Nodakenin Through Muscarinic, Dopaminergic, and Serotonergic Receptor Modulation: Combined Experimental and Computational Approach.Cell biochemistry and biophysics · 2026Article
- Cannabidiol reduces LPS-induced inflammatory response in the human placenta by reducing NF-κB translocation.Journal of cannabis research · 2025Article
- Cannabinoid Hyperemesis Syndrome, 2016 to 2022.JAMA network open · 2025Article
- Atypical Presentation of Spontaneous Pneumomediastinum Secondary to Cannabinoid Hyperemesis Syndrome.Cureus · 2025Article
- Cannabinoid Hyperemesis Syndrome: A Rare Cause of Severe Abdominal Pain and Hyperlactataemia.Cureus · 2025Article
- Unraveling the Enigma of Cannabinoid Hyperemesis Syndrome: A Narrative Review of Diagnosis and Management.Cureus · 2025Review
- Cannabis Hyperemesis Syndrome in Youth: Clinical Insights and Public Health Implications.International journal of environmental research and public health · 2025Review
- Article
- Review
- The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.AIMS neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabis, derived from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.